GE Appliances Doubles Down on U.S. Manufacturing With $490 Million Laundry Plant Investment at Its Global Headquarters in Louisville, Kentucky
LOUISVILLE, Ky.--(BUSINESS WIRE)--GE Appliances, a Haier company, today announced a $490 million investment at its Louisville, Kentucky global headquarters and largest manufacturing site to create its most advanced manufacturing plant for production of clothes washers. The project will reshore production of the GE Profile™ UltraFast Combo Washer/Dryer and the GE® and GE Profile™ UltraFresh Front Load Washer line-up from China, creating 800 new, full-time jobs and cementing Kentucky's position as a global hub for advanced appliance manufacturing. This investment positions the company to become the biggest American washer manufacturer, builds on GE Appliances' 10-year, $3.5 billion investment in U.S. manufacturing, and reinforces its position as America's #1 appliance company. 1
'We are bringing laundry production to our global headquarters in Louisville because manufacturing in the U.S. is fundamental to our 'zero-distance' business strategy to make appliances as close as possible to our customers and consumers,' said Kevin Nolan, president & CEO, GE Appliances. 'This decision is our most recent product reshoring and aligns with the current economic and policy environment.'
'Today's announcement further secures Louisville as the global headquarters of GE Appliances, a Haier company, and brings more world-class, unparalleled appliance manufacturing back to the United States,' said Kentucky Gov. Andy Beshear. 'This new investment strengthens one of our vital Kentucky assets and underscores our state's reputation as America's destination of choice for advanced manufacturing and job creation.'
A Model Factory for the Appliance Industry
This investment will move production of more than 15 models of front load washers to Building 2 at Appliance Park – bringing the total area of clothes care production to the equivalent of 33 football fields. Next door, Building 1 at Appliance Park produces top load washers and front load dryers. Building 2 will be redesigned as a model factory, showcasing the latest in automation, robotics, and material-handling technologies, including AGVs (Automated Guided Vehicles) and AMRs (Autonomous Mobile Robots). The plant is vertically integrated and will include in-house manufacturing of critical parts such as stainless-steel baskets and cabinets, high-precision metal stamping and forming, and injection-molding and production equipment, delivering products with the quality, craftsmanship and market-leading features consumers have come to expect from products carrying GE Appliances' brands. The new manufacturing lines will open in 2027.
Product Highlights That Wow
GE Profile™ UltraFast Combo Washer/Dryer – This ventless 2-in-1 laundry appliance washes and dries full-sized loads in the same drum, eliminating the transfer step and delivering a large laundry load ready to wear in about two hours 2. In addition to time-saving capabilities, the machine also saves energy with ventless heat pump technology and offers the ultimate installation flexibility — fitting anywhere with a water hookup and 120v plug. This game-changing innovation revolutionized the laundry chore by giving time back to American consumers.
GE Profile™ Front Load Washer with UltraFresh™ Vent System+ – This revolutionary washer line-up was thoughtfully engineered to remove the dreaded front load odor, eliminating the need for owners to leave the door open after each load. A three-part solution includes a wider gasket to better drain the water, the UltraFresh Vent System with OdorBlock™ that circulates fresh air to keep the basket dry, and Microban® Antimicrobial Technology built in to help defend against the growth of odor-causing bacteria.
'Manufacturing in Louisville puts production closer to our designers, engineers and consumers so that together we can create our most innovative laundry platforms,' said Lee Lagomarcino, vice president, clothes care, GE Appliances. 'The team has already developed new solutions for American households and can't wait to get started making them. The new full-size capacity products have features that save time and offer unparalleled convenience. We created the full-size washer/dryer combo laundry category, and we intend to maintain our leadership position with consumers.'
Support from the City and Commonwealth
The Kentucky Economic Development Finance Authority (KEDFA) preliminarily approved performance-based incentives in support of the project under the Kentucky Business Investment program, workforce training grants through the Kentucky Skills Network and funds to support the modernizing the building. Final amounts will be determined upon GE Appliances meeting job retention and investment targets.
'I am thrilled GE Appliances will continue to build the world's best appliances at its global headquarters in Louisville,' said Louisville Mayor Craig Greenberg. 'This half-billion-dollar investment is a huge deal that will create 800 good, local jobs and secure GE Appliances' growth in Louisville for the next generation.'
GE Appliances' work to design, manufacture and service products for consumers across America contributes $30.2 billion to the U.S. economy. GE Appliances' investment of $3 billion in plant and equipment, R&D, new product development and logistics over the previous eight years is greater than any other appliance company in America. These investments have helped double our company, create more than 4,000 new jobs and rippled throughout the U.S. economy to create an additional 98,000 jobs with suppliers, customers and other companies.
GE Appliances' 2024 Economic Impact Report for Kentucky shows:
$12.8 billion contributed to Kentucky's Gross Domestic Product
8,000 direct Kentucky employees
30,500 additional Kentucky jobs supported through GE Appliances' economic activity
$655 million generated in state and local taxes
$318 million spent annually with 481 Kentucky suppliers
About GE Appliances, a Haier company
At GE Appliances, a Haier company, we come together to make good things, for life. Headquartered in Louisville, Kentucky, we are a leading U.S. manufacturer of home appliances with 15,500 team members nationwide. GE Appliances, found in half of all U.S. homes, is proud to be rated America's #1 Appliance Company 1, trusted by millions of families nationwide. We manufacture and sell products under the Monogram™, Café™, GE Profile™, GE®, Haier™, and Hotpoint™ brands. Our operations support nearly 98,000 additional American jobs and represent an investment of more than $3.5 billion since 2016. We are deeply committed to the communities where we live and work, passionate about getting closer to our product users to understand their needs and driven by the belief that there's always a better way.
To learn more about our company, brands, career opportunities, and impact, visit geappliancesco.com or connect with us on LinkedIn.
1 OpenBrand Consumer Tracking Survey, Q1 – Q4 2024, Based on Volume of Total Majors/MO/RAC – Retail Units
2 Tested using a 10lb DOE (Department of Energy) or typical mixed load on the Normal Wash + Dry Cycle Eco Dry setting.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
36 minutes ago
- Business Wire
Verasonics Announces Enhancements to the Vantage ® NXT Research Ultrasound Platform Designed to Further Improve Capabilities in Ultrasound Research and Product Development
KIRKLAND, Wash.--(BUSINESS WIRE)-- Verasonics, Inc., the leader in research ultrasound, today announced the release of new systems and features for the Vantage NXT Research Ultrasound Platform to advance ultrasound research and product development. New enhancements include Vantage NXT 32LE and 64 System configuration models and Acquisition SDK Option features. This release will be available to all Vantage NXT customers today. 'We are excited to showcase these new enhancements with configurations and features to advance research in Biomedical, Materials Science and Industrial R&D arenas.' Enhancements to Vantage NXT in the Update include: Vantage NXT 32LE and Vantage NXT 64 system models – Available in Mid- and High-Frequency ranges, these 32- and 64-channel model configurations are ideal for customers requiring low-channel data acquisition with transmit and receive data as well as Non-Destructive Evaluation (NDE) / Non-Destructive Testing (NDT) and Materials Science research. In addition, Verasonics has released two additional Universal Transducer Adapters (UTAs) for Vantage NXT – the NXT UTA 260-MUX and NXT UTA 408-GE MUX. Acquisition SDK Option – Launched in March, the Acquisition SDK now includes programming capability for the NXT UTA 256 Direct and NXT UTA 64 LEMO, as well as the Extended Transmit Option and Vantage NXT HIFU configurations. Acquisition SDK, a C-based API, allows Vantage NXT users to program their system without MATLAB ® dependencies. The Acquisition SDK, which is comprised of a C-API, example code, and documentation, offers users similar data structures and naming conventions to those of the MATLAB Programming Model to simplify the porting of existing sequences to the Acquisition SDK environment. The Acquisition SDK is an ideal complement for users who aim to develop applications intended for commercialization or for integration of their legacy or third-party software to run on the Vantage NXT Platform. These enhancements in this update expand features for Vantage NXT users and provide more options to those considering an uptrade from the Vantage Research Ultrasound System to the Vantage NXT Research Ultrasound System. Contact sales@ regarding uptrade options. 'The Vantage NXT platform continues to expand to meet the needs of academic and commercial customers across the globe,' said Jon K. Daigle, President and Chief Executive Officer at Verasonics. 'We are excited to showcase these new enhancements with configurations and features to advance research in Biomedical, Materials Science and Industrial R&D arenas.' Visit our website for more information about Vantage NXT Research Ultrasound Systems. About Verasonics, Inc. Verasonics is a privately held company founded in 2001, with headquarters in Kirkland, Washington, USA. Verasonics, the leader in research ultrasound, is focused on providing researchers and developers with the most advanced and flexible tools enabling them to develop new algorithms and products used in biomedical ultrasound, materials science, earth sciences, and the physics of acoustics and ultrasonics. Verasonics also licenses its technology to companies for use in their commercial products. Researchers in countries across North and South America, Europe, Asia and Oceania routinely use Verasonics product solutions to advance the art and science of ultrasound through their own research efforts. Learn more by visiting the Verasonics website or following us on LinkedIn and X (Formerly Twitter).
Yahoo
an hour ago
- Yahoo
Orano Med Inaugurates Expansion of its U.S. Research and Development Center in Texas
PARIS, June 26, 2025--(BUSINESS WIRE)--Orano Med, a subsidiary of the Orano Group and a pioneer in radioligand therapies in oncology, today inaugurated the expansion of its main Research and Development Center located in Plano, Texas (USA). This strategic facility is dedicated to developing novel radiopharmaceuticals and conducting preclinical research focused on targeted alpha therapies using lead-212 (212Pb), an innovative and promising approach against various types of cancer. The site hosts the R&D teams of Orano Med as well as those of its subsidiary Macrocyclics, a manufacturer of customized chelating agents. With an investment of over $5 million, Orano Med has expanded its R&D Center by approximately 11,000 ft². The expansion includes around 5,000 ft² of new laboratory space, enabling the advancement of a growing pipeline and doubling the Good Manufacturing Practice (GMP) production capacity for early clinical trial supply. In addition, about 5,500 ft² of new office space has been added to accommodate the site's growing team, whose headcount has doubled over the past four years. Overall, this represents about a 50% increase in space compared to the pre-existing facility. Julien Torgue, Chief Scientific Officer of Orano Med, stated: "The expansion of our R&D center enhances our ability to develop lead-212-based radioligand therapies by giving our teams the resources they need to advance a growing pipeline of drug candidates through to the clinic. With an integrated platform, cutting-edge equipment and a focused scientific strategy, we are well positioned to support both our internal developments and collaborations with partners." Orano Med's R&D platform is fully integrated, combining cutting-edge equipment and a highly experienced team to advance the development of next-generation cancer therapies. The company can carry out the full range of preclinical development studies, including in vivo and Chemistry, Manufacturing and Controls (CMC) studies, onsite. Orano Med conducts both in-house research programs and collaborative developments with biotech and pharmaceutical partners. This integrated approach ensures a rapid and reliable transition from research to clinical phases. While the primary mission of the research and development center is therapeutic development, the facility also serves as production hub for lead-212 based drug candidates for early-stage clinical trials in the U.S. This expansion demonstrates Orano Med's strong commitment to innovation and leadership in the field of radioligand therapies, accelerating the development of new treatment options for patients worldwide. A celebration was held on-site with local teams and Orano Med's Executive Committee to mark this important milestone. During the event, Orano Med also unveiled the new name of the facility: Drug Development and Preclinical Unit (DDPU) – George de Hevesy Center Arnaud Lesegretain, President and Chief Executive Officer of Orano Med, added: "This expansion marks an important step in Orano Med's growth at our Plano site, which has played a key role since the inception of the company 15 years ago. It reinforces our world-class R&D capabilities in the U.S. and strengthens our ability to deliver innovative targeted alpha therapies by supporting early-stage development in a fully integrated environment." About Orano Med Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). AlphaMedix, its most advanced asset in clinical development for GEP-NETs tumors, received Breakthrough Designation from the FDA in 2024. The company is advancing several potential treatments using 212Pb combined with various targeting agents through clinical and preclinical studies. Orano Med has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US. It is expanding its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe and building a unique, independent, and fully integrated industrial platform to serve the needs of patients globally. For more information, please visit: About Orano As a recognized international leading operator in the field of nuclear materials, Orano delivers solutions to address present and future global energy and health challenges. Its expertise and mastery of cutting-edge technologies enable Orano to offer its customers high value-added products and services throughout the entire fuel cycle. Every day, the Orano group's 17,500 employees draw on their skills, unwavering dedication to safety and constant quest for innovation, with the commitment to develop know-how in the transformation and control of nuclear materials, for the climate and for a healthy and resource-efficient world, now and tomorrow. Orano, giving nuclear energy its full value. About Targeted Alpha Therapy Targeted alpha therapy (TAT) relies on a simple concept: combining the ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha-emitting radioisotopes. Alpha decay consists of the emission of a helium nucleus (alpha particle) together with very high linear energy transfer and a range emission of only few cell layers, resulting in irreparable double strand DNA breaks in cells adjacent only to area of alpha emission. This approach results in an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. As a result, alpha emitters are considered as the most powerful payloads to be found for targeted therapies. View source version on Contacts Mike SinclairHalsin Partnersmsinclair@
Business Wire
an hour ago
- Business Wire
Orano Med Inaugurates Expansion of its U.S. Research and Development Center in Texas
PARIS--(BUSINESS WIRE)--Orano Med, a subsidiary of the Orano Group and a pioneer in radioligand therapies in oncology, today inaugurated the expansion of its main Research and Development Center located in Plano, Texas (USA). This strategic facility is dedicated to developing novel radiopharmaceuticals and conducting preclinical research focused on targeted alpha therapies using lead-212 (212 Pb), an innovative and promising approach against various types of cancer. The site hosts the R&D teams of Orano Med as well as those of its subsidiary Macrocyclics, a manufacturer of customized chelating agents. 'The expansion of our R&D center enhances our ability to develop lead-212-based radioligand therapies by giving our teams the resources they need to advance a growing pipeline of drug candidates through to the clinic." Share With an investment of over $5 million, Orano Med has expanded its R&D Center by approximately 11,000 ft². The expansion includes around 5,000 ft² of new laboratory space, enabling the advancement of a growing pipeline and doubling the Good Manufacturing Practice (GMP) production capacity for early clinical trial supply. In addition, about 5,500 ft² of new office space has been added to accommodate the site's growing team, whose headcount has doubled over the past four years. Overall, this represents about a 50% increase in space compared to the pre-existing facility. Julien Torgue, Chief Scientific Officer of Orano Med, stated: 'The expansion of our R&D center enhances our ability to develop lead-212-based radioligand therapies by giving our teams the resources they need to advance a growing pipeline of drug candidates through to the clinic. With an integrated platform, cutting-edge equipment and a focused scientific strategy, we are well positioned to support both our internal developments and collaborations with partners.' Orano Med's R&D platform is fully integrated, combining cutting-edge equipment and a highly experienced team to advance the development of next-generation cancer therapies. The company can carry out the full range of preclinical development studies, including in vivo and Chemistry, Manufacturing and Controls (CMC) studies, onsite. Orano Med conducts both in-house research programs and collaborative developments with biotech and pharmaceutical partners. This integrated approach ensures a rapid and reliable transition from research to clinical phases. While the primary mission of the research and development center is therapeutic development, the facility also serves as production hub for lead-212 based drug candidates for early-stage clinical trials in the U.S. This expansion demonstrates Orano Med's strong commitment to innovation and leadership in the field of radioligand therapies, accelerating the development of new treatment options for patients worldwide. A celebration was held on-site with local teams and Orano Med's Executive Committee to mark this important milestone. During the event, Orano Med also unveiled the new name of the facility: Drug Development and Preclinical Unit (DDPU) – George de Hevesy Center Arnaud Lesegretain, President and Chief Executive Officer of Orano Med, added: 'This expansion marks an important step in Orano Med's growth at our Plano site, which has played a key role since the inception of the company 15 years ago. It reinforces our world-class R&D capabilities in the U.S. and strengthens our ability to deliver innovative targeted alpha therapies by supporting early-stage development in a fully integrated environment.' About Orano Med Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212 Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). AlphaMedix, its most advanced asset in clinical development for GEP-NETs tumors, received Breakthrough Designation from the FDA in 2024. The company is advancing several potential treatments using 212 Pb combined with various targeting agents through clinical and preclinical studies. Orano Med has 212 Pb manufacturing facilities, laboratories, and R&D centers in France and in the US. It is expanding its GMP-manufacturing capacities for 212 Pb radiolabeled pharmaceuticals in North America and Europe and building a unique, independent, and fully integrated industrial platform to serve the needs of patients globally. For more information, please visit: About Orano As a recognized international leading operator in the field of nuclear materials, Orano delivers solutions to address present and future global energy and health challenges. Its expertise and mastery of cutting-edge technologies enable Orano to offer its customers high value-added products and services throughout the entire fuel cycle. Every day, the Orano group's 17,500 employees draw on their skills, unwavering dedication to safety and constant quest for innovation, with the commitment to develop know-how in the transformation and control of nuclear materials, for the climate and for a healthy and resource-efficient world, now and tomorrow. Orano, giving nuclear energy its full value. About Targeted Alpha Therapy Targeted alpha therapy (TAT) relies on a simple concept: combining the ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha-emitting radioisotopes. Alpha decay consists of the emission of a helium nucleus (alpha particle) together with very high linear energy transfer and a range emission of only few cell layers, resulting in irreparable double strand DNA breaks in cells adjacent only to area of alpha emission. This approach results in an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. As a result, alpha emitters are considered as the most powerful payloads to be found for targeted therapies.
